FDA — authorised 4 February 2022
- Application: BLA761164
- Marketing authorisation holder: RECORDATI RARE DISEASES, INC.
- Local brand name: ENJAYMO
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 ENJAYMO in United States
FDA authorised ENJAYMO on 4 February 2022
Marketing authorisation
ENJAYMO in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in United States
Frequently asked questions
Is ENJAYMO approved in United States?
Yes. FDA authorised it on 4 February 2022.
Who is the marketing authorisation holder for ENJAYMO in United States?
RECORDATI RARE DISEASES, INC. holds the US marketing authorisation.